TWI786777B - Sarm1之抑制劑 - Google Patents

Sarm1之抑制劑 Download PDF

Info

Publication number
TWI786777B
TWI786777B TW110130799A TW110130799A TWI786777B TW I786777 B TWI786777 B TW I786777B TW 110130799 A TW110130799 A TW 110130799A TW 110130799 A TW110130799 A TW 110130799A TW I786777 B TWI786777 B TW I786777B
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
chiral
mmol
Prior art date
Application number
TW110130799A
Other languages
English (en)
Chinese (zh)
Other versions
TW202214597A (zh
Inventor
陶德 波薩納克
拉杰什 德芙拉吉
羅伯特 歐文 修斯
安德鲁 布雷利
派克 理查 安德魯 傑瑞斯
雪莉 安妮 帕勒特
Original Assignee
美商達薩瑪治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商達薩瑪治療公司 filed Critical 美商達薩瑪治療公司
Publication of TW202214597A publication Critical patent/TW202214597A/zh
Application granted granted Critical
Publication of TWI786777B publication Critical patent/TWI786777B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110130799A 2020-08-24 2021-08-20 Sarm1之抑制劑 TWI786777B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063069408P 2020-08-24 2020-08-24
US63/069,408 2020-08-24
US202163142398P 2021-01-27 2021-01-27
US63/142,398 2021-01-27

Publications (2)

Publication Number Publication Date
TW202214597A TW202214597A (zh) 2022-04-16
TWI786777B true TWI786777B (zh) 2022-12-11

Family

ID=77775005

Family Applications (2)

Application Number Title Priority Date Filing Date
TW110130799A TWI786777B (zh) 2020-08-24 2021-08-20 Sarm1之抑制劑
TW111144632A TW202334117A (zh) 2020-08-24 2021-08-20 Ｓａｒｍ１之抑制劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW111144632A TW202334117A (zh) 2020-08-24 2021-08-20 Ｓａｒｍ１之抑制劑

Country Status (18)

Country Link
US (2) US12043613B2 (OSRAM)
EP (1) EP4200293A1 (OSRAM)
JP (2) JP7349046B2 (OSRAM)
KR (1) KR20230057396A (OSRAM)
AU (2) AU2021333558C1 (OSRAM)
BR (1) BR112023002575A2 (OSRAM)
CA (1) CA3189181A1 (OSRAM)
CL (1) CL2023000525A1 (OSRAM)
CO (1) CO2023001975A2 (OSRAM)
CR (1) CR20230113A (OSRAM)
DO (1) DOP2023000038A (OSRAM)
EC (1) ECSP23012981A (OSRAM)
IL (1) IL300586A (OSRAM)
MX (1) MX2023002256A (OSRAM)
PE (1) PE20230737A1 (OSRAM)
TW (2) TWI786777B (OSRAM)
WO (1) WO2022046606A1 (OSRAM)
ZA (1) ZA202301801B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12083114B2 (en) 2018-12-19 2024-09-10 Disarm Therapeutics, Inc. Inhibitors of SARM1 in combination with neuro-protective agents
US12404265B2 (en) 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
US11945796B2 (en) 2020-09-16 2024-04-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors
AU2022320699A1 (en) 2021-07-28 2024-02-29 Nura Bio, Inc. Substituted pyridine derivatives as sarm1 inhibitors
EP4558148A2 (en) * 2022-07-21 2025-05-28 Amylyx Pharmaceuticals Inc. Oligonucleotide compositions and methods thereof
CN120457107A (zh) * 2022-12-15 2025-08-08 维泰瑞隆有限公司 Sarm1调节剂、其制备和用途
WO2024158775A1 (en) 2023-01-24 2024-08-02 Disarm Therapeutics, Inc. Pyridazines as sarm1 inhibitors
WO2024222835A1 (en) * 2023-04-27 2024-10-31 Sironax Ltd. Sarm1 modulators, preparations, and uses thereof
CN119219603A (zh) * 2023-06-28 2024-12-31 科辉智药(深圳)新药研究中心有限公司 Sarm1酶活性抑制剂及其用途
WO2025045746A1 (en) * 2023-08-25 2025-03-06 F. Hoffmann-La Roche Ag Pyrazole derivatives as sarm1 inhibitors useful for the treatment of neurodegenerative disorders
WO2025049184A1 (en) 2023-08-25 2025-03-06 Eli Lilly And Company (s)-3-((6-fluoropyridin-3-yl)methyl)-1-(5-(pyridin-4-yl)-4h-1,2,4-triazol-3-yl)piperidin-2-one benzenesulfonate
WO2025076017A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Carbamates for use as sarm1 inhibitors
WO2025076088A1 (en) * 2023-10-05 2025-04-10 Genentech, Inc. Lactams for use as sarm1 inhibitors
WO2025157895A1 (en) 2024-01-25 2025-07-31 UCB Biopharma SRL Pyrrolidinone derivatives

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018114662A1 (de) * 2016-12-22 2018-06-28 Bayer Cropscience Aktiengesellschaft Substituierte 1,2,4-thiadiazolylpyrrolone und 1,2,4-thiadiazolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe
WO2019236890A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2302417A1 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
US6787555B2 (en) 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity
CA2504320A1 (en) 2002-10-30 2004-05-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of rock and other protein kinases
EP1581222A2 (en) 2003-01-02 2005-10-05 Millennium Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR INHIBITING TGF-&bgr;
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
ATE464303T1 (de) 2004-04-28 2010-04-15 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
RU2423351C2 (ru) 2004-12-16 2011-07-10 Вертекс Фармасьютикалз Инкорпорейтед Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний
CA2656159C (en) 2006-06-28 2014-12-16 Aska Pharmaceutical Co., Ltd. Pyridylisoxazole derivatives
BRPI0717097A2 (pt) 2006-09-21 2013-11-26 Novartis Ag Derivados de pirrol úteis para o tratamento de doenças mediadas por citocina
US8940771B2 (en) 2007-12-20 2015-01-27 Novartis Ag Organic compounds
WO2009080705A2 (en) 2007-12-20 2009-07-02 Novartis Ag Bis-thiazole derivatives, process for their preparation and their use as medicaments
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
WO2010093849A2 (en) 2009-02-13 2010-08-19 Amgen Inc. Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions
US20120328629A1 (en) 2011-06-24 2012-12-27 University Of Miami Therapeutic Applications Targeting SARM1
EP2914591B1 (en) 2012-11-03 2017-10-11 Boehringer Ingelheim International GmbH Inhibitors of cytomegalovirus
WO2014099694A1 (en) 2012-12-19 2014-06-26 Merck Sharp & Dohme Corp. FACTOR IXa INHIBITORS
RU2570907C2 (ru) 2013-10-21 2015-12-20 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа.
WO2015084936A1 (en) 2013-12-04 2015-06-11 The Scripps Research Institute Novel compounds as jnk kinase inhibitors
US11357800B2 (en) 2016-08-16 2022-06-14 Henry Ford Health System Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies
JP7044789B2 (ja) 2016-09-24 2022-03-30 ワシントン・ユニバーシティ Ｓａｒｍ１ ｎａｄアーゼ活性の阻害剤およびその使用
UY37512A (es) 2016-12-09 2019-04-30 Vertex Pharma Compuestos pirazol 1,3-sustituido útiles para la reducción de los niveles de ácidos grasos de cadena muy larga
WO2018114663A1 (de) 2016-12-22 2018-06-28 Bayer Cropscience Aktiengesellschaft Substituierte azolylpyrrolone und azolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe
AU2018388406B2 (en) 2017-12-22 2023-07-06 HiberCell Inc. Aryl-bipyridine amine derivatives as phosphatidylinositol phosphate kinase inhibitors
JP2021527125A (ja) 2018-06-07 2021-10-11 ディサーム・セラピューティクス・インコーポレイテッドＤｉｓａｒｍ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｓａｒｍ１阻害剤
JP7478142B2 (ja) 2018-06-07 2024-05-02 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１阻害剤
US12084436B2 (en) 2019-01-30 2024-09-10 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7289375B2 (ja) 2019-06-06 2023-06-09 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１の阻害剤
US20220340546A1 (en) 2019-06-14 2022-10-27 Disarm Therapeutics, Inc. Inhibitors of sarm1
MX2022000950A (es) 2019-07-22 2022-02-14 Bayer Ag 5-amino pirazoles y triazoles como plaguicidas.
EP4028013A4 (en) 2019-09-12 2023-10-18 Disarm Therapeutics, Inc. MRSA1 INHIBITORS
AU2020380395A1 (en) 2019-11-05 2022-05-26 Dermira, Inc. MrgprX2 antagonists for the treatment of inflammatory disorders
KR20220164471A (ko) 2020-01-07 2022-12-13 디스암 테라퓨틱스, 인크. Sarm1의 억제제
JP7477642B2 (ja) 2020-04-09 2024-05-01 ディスアーム セラピューティクス， インコーポレイテッド Ｓａｒｍ１の阻害剤
ES3049432T3 (en) 2020-04-09 2025-12-16 Disarm Therapeutics Inc Indazole derivatives as inhibitors of sarm1
US12404265B2 (en) 2020-08-04 2025-09-02 Nura Bio, Inc. Substituted pyridine derivatives as SARM1 inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018114662A1 (de) * 2016-12-22 2018-06-28 Bayer Cropscience Aktiengesellschaft Substituierte 1,2,4-thiadiazolylpyrrolone und 1,2,4-thiadiazolylhydantoine sowie deren salze und ihre verwendung als herbizide wirkstoffe
WO2019236890A1 (en) * 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1

Also Published As

Publication number Publication date
JP2023535236A (ja) 2023-08-16
PE20230737A1 (es) 2023-05-03
JP7756130B2 (ja) 2025-10-17
US20240376083A1 (en) 2024-11-14
WO2022046606A1 (en) 2022-03-03
DOP2023000038A (es) 2023-03-15
US20220056013A1 (en) 2022-02-24
AU2021333558A1 (en) 2023-03-02
KR20230057396A (ko) 2023-04-28
MX2023002256A (es) 2023-03-17
AU2021333558B2 (en) 2024-02-22
AU2021333558C1 (en) 2024-06-20
JP2024016014A (ja) 2024-02-06
EP4200293A1 (en) 2023-06-28
TW202530197A (zh) 2025-08-01
CA3189181A1 (en) 2022-03-03
ECSP23012981A (es) 2023-03-31
CL2023000525A1 (es) 2023-09-15
US12043613B2 (en) 2024-07-23
BR112023002575A2 (pt) 2023-03-07
CO2023001975A2 (es) 2023-03-07
IL300586A (en) 2023-04-01
AU2024203373A1 (en) 2024-06-13
ZA202301801B (en) 2024-09-25
TW202334117A (zh) 2023-09-01
TW202214597A (zh) 2022-04-16
JP7349046B2 (ja) 2023-09-21
CR20230113A (es) 2023-04-14

Similar Documents

Publication Publication Date Title
TWI786777B (zh) Sarm1之抑制劑
CN115175900B (zh) Sarm1的抑制剂
CN114728007B (zh) Sarm1的抑制剂
JP7319395B2 (ja) Ｓａｒｍ１の阻害剤
CN116075511B (zh) 作为sarm1抑制剂的稠合吡唑衍生物
CN116568678B (zh) Sarm1的苯并吡唑抑制剂
CN115916764B (zh) 作为sarm1抑制剂的吲唑衍生物
JP2022534544A (ja) Ｓａｒｍ１の阻害剤
JP2020514361A (ja) ９，１０，１１，１２−テトラヒドロ−８ｈ−［１，４］ジアゼピノ［５’，６’：４，５］チエノ［３，２−ｆ］キノリン−８−オン化合物およびその使用
TWI904906B (zh) Sarm1之抑制劑
HK40075925A (en) Inhibitors of sarm1
EA048703B1 (ru) Ингибиторы sarm1
CN116940569A (zh) Sarm1抑制剂